Back to today’s briefing

Story perspectives

Olezarsen Slashes Triglycerides, Boosts Ionis Stock 34.8%

9/2/2025

33 5

Summary

Story summary

Ionis Pharmaceuticals' experimental drug, olezarsen, reduced triglycerides by up to 72% in severe hypertriglyceridemia patients.
Patients saw an 85% decrease in pancreatitis events compared to placebo.
The company intends to seek FDA approval for olezarsen by the end of the year.
Following the announcement, Ionis stock rose nearly 34.8%.

1 of 1

Story summary

Ionis Pharmaceuticals' experimental drug, olezarsen, reduced triglycerides by up to 72% in severe hypertriglyceridemia patients.
Patients saw an 85% decrease in pancreatitis events compared to placebo.
The company intends to seek FDA approval for olezarsen by the end of the year.
Following the announcement, Ionis stock rose nearly 34.8%.